

Global EGFR Inhibitors for Lung Cancer Market Growth 2022-2028

<https://marketpublishers.com/r/GAC6B0D9A0EBEN.html>

Date: November 2022

Pages: 118

Price: US\$ 3,660.00 (Single User License)

ID: GAC6B0D9A0EBEN

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

The global market for EGFR Inhibitors for Lung Cancer is estimated to increase from US\$ million in 2021 to reach US\$ million by 2028, exhibiting a CAGR of % during 2022-2028. Keeping in mind the uncertainties of COVID-19 and Russia-Ukraine War, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.

The APAC EGFR Inhibitors for Lung Cancer market is expected at value of US\$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.

The United States EGFR Inhibitors for Lung Cancer market is expected at value of US\$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.

The Europe EGFR Inhibitors for Lung Cancer market is expected at value of US\$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.

The China EGFR Inhibitors for Lung Cancer market is expected at value of US\$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.

Global key EGFR Inhibitors for Lung Cancer players cover Pfizer, AstraZeneca, Genentech (Roche Group), Beta Pharma and Mylan, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.

Report Coverage

This latest report provides a deep insight into the global EGFR Inhibitors for Lung Cancer market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, value chain analysis, etc.

This report aims to provide a comprehensive picture of the global EGFR Inhibitors for Lung Cancer market, with both quantitative and qualitative data, to help readers understand how the EGFR Inhibitors for Lung Cancer market scenario changed across the globe during the pandemic and Russia-Ukraine War.

The base year considered for analyses is 2021, while the market estimates and forecasts are given from 2022 to 2028. The market estimates are provided in terms of revenue in USD millions and volume in K Units.

Market Segmentation:

The study segments the EGFR Inhibitors for Lung Cancer market and forecasts the market size by Type (Gefitinib, Afatinib and Osimertinib), by Application (Medical Care, Experiment and Others), and region (APAC, Americas, Europe, and Middle East & Africa).

Segmentation by type

Gefitinib

Afatinib

Osimertinib

Other

Segmentation by application

Medical Care

Experiment

Others

Segmentation by region

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

Major companies covered

Pfizer

AstraZeneca

Genentech (Roche Group)

Beta Pharma

Mylan

Boehringer Ingelheim

Teva Pharmaceuticals

Qilu Pharmaceutical

Betta Pharmaceuticals

Haosen Pharmaceutical

ARIAD Pharmaceuticals

HUTCHMED

Shanghai Ellis

Genvio Pharma

Everest Pharmaceuticals

Incepta Pharmaceuticals

Jiangsu Hengrui Medicine

Chapter Introduction

Chapter 1: Scope of EGFR Inhibitors for Lung Cancer, Research Methodology, etc.

Chapter 2: Executive Summary, global EGFR Inhibitors for Lung Cancer market size (sales and revenue) and CAGR, EGFR Inhibitors for Lung Cancer market size by region, by type, by application, historical data from 2017 to 2022, and forecast to 2028.

Chapter 3: EGFR Inhibitors for Lung Cancer sales, revenue, average price, global market share, and industry ranking by company, 2017-2022

Chapter 4: Global EGFR Inhibitors for Lung Cancer sales and revenue by region and by country. Country specific data and market value analysis for the U.S., Canada, Europe, China, Japan, South Korea, Southeast Asia, India, Latin America and Middle East & Africa.

Chapter 5, 6, 7, 8: Americas, APAC, Europe, Middle East & Africa, sales segment by country, by type, and type.

Chapter 9: Analysis of the current market trends, market forecast, opportunities and economic trends that are affecting the future marketplace

Chapter 10: Manufacturing cost structure analysis

Chapter 11: Sales channel, distributors, and customers

Chapter 12: Global EGFR Inhibitors for Lung Cancer market size forecast by region, by country, by type, and application.

Chapter 13: Comprehensive company profiles of the leading players, including Pfizer, AstraZeneca, Genentech (Roche Group), Beta Pharma, Mylan, Boehringer Ingelheim, Teva Pharmaceuticals, Qilu Pharmaceutical and Betta Pharmaceuticals, etc.

Chapter 14: Research Findings and Conclusion

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered

2 EXECUTIVE SUMMARY

- 2.1 World Market Overview
 - 2.1.1 Global EGFR Inhibitors for Lung Cancer Annual Sales 2017-2028
 - 2.1.2 World Current & Future Analysis for EGFR Inhibitors for Lung Cancer by Geographic Region, 2017, 2022 & 2028
 - 2.1.3 World Current & Future Analysis for EGFR Inhibitors for Lung Cancer by Country/Region, 2017, 2022 & 2028
- 2.2 EGFR Inhibitors for Lung Cancer Segment by Type
 - 2.2.1 Gefitinib
 - 2.2.2 Afatinib
 - 2.2.3 Osimertinib
 - 2.2.4 Other
- 2.3 EGFR Inhibitors for Lung Cancer Sales by Type
 - 2.3.1 Global EGFR Inhibitors for Lung Cancer Sales Market Share by Type (2017-2022)
 - 2.3.2 Global EGFR Inhibitors for Lung Cancer Revenue and Market Share by Type (2017-2022)
 - 2.3.3 Global EGFR Inhibitors for Lung Cancer Sale Price by Type (2017-2022)
- 2.4 EGFR Inhibitors for Lung Cancer Segment by Application
 - 2.4.1 Medical Care
 - 2.4.2 Experiment
 - 2.4.3 Others
- 2.5 EGFR Inhibitors for Lung Cancer Sales by Application
 - 2.5.1 Global EGFR Inhibitors for Lung Cancer Sale Market Share by Application (2017-2022)
 - 2.5.2 Global EGFR Inhibitors for Lung Cancer Revenue and Market Share by

Application (2017-2022)

2.5.3 Global EGFR Inhibitors for Lung Cancer Sale Price by Application (2017-2022)

3 GLOBAL EGFR INHIBITORS FOR LUNG CANCER BY COMPANY

3.1 Global EGFR Inhibitors for Lung Cancer Breakdown Data by Company

3.1.1 Global EGFR Inhibitors for Lung Cancer Annual Sales by Company (2020-2022)

3.1.2 Global EGFR Inhibitors for Lung Cancer Sales Market Share by Company (2020-2022)

3.2 Global EGFR Inhibitors for Lung Cancer Annual Revenue by Company (2020-2022)

3.2.1 Global EGFR Inhibitors for Lung Cancer Revenue by Company (2020-2022)

3.2.2 Global EGFR Inhibitors for Lung Cancer Revenue Market Share by Company (2020-2022)

3.3 Global EGFR Inhibitors for Lung Cancer Sale Price by Company

3.4 Key Manufacturers EGFR Inhibitors for Lung Cancer Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers EGFR Inhibitors for Lung Cancer Product Location Distribution

3.4.2 Players EGFR Inhibitors for Lung Cancer Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)

3.6 New Products and Potential Entrants

3.7 Mergers & Acquisitions, Expansion

4 WORLD HISTORIC REVIEW FOR EGFR INHIBITORS FOR LUNG CANCER BY GEOGRAPHIC REGION

4.1 World Historic EGFR Inhibitors for Lung Cancer Market Size by Geographic Region (2017-2022)

4.1.1 Global EGFR Inhibitors for Lung Cancer Annual Sales by Geographic Region (2017-2022)

4.1.2 Global EGFR Inhibitors for Lung Cancer Annual Revenue by Geographic Region

4.2 World Historic EGFR Inhibitors for Lung Cancer Market Size by Country/Region (2017-2022)

4.2.1 Global EGFR Inhibitors for Lung Cancer Annual Sales by Country/Region (2017-2022)

4.2.2 Global EGFR Inhibitors for Lung Cancer Annual Revenue by Country/Region

4.3 Americas EGFR Inhibitors for Lung Cancer Sales Growth

- 4.4 APAC EGFR Inhibitors for Lung Cancer Sales Growth
- 4.5 Europe EGFR Inhibitors for Lung Cancer Sales Growth
- 4.6 Middle East & Africa EGFR Inhibitors for Lung Cancer Sales Growth

5 AMERICAS

- 5.1 Americas EGFR Inhibitors for Lung Cancer Sales by Country
 - 5.1.1 Americas EGFR Inhibitors for Lung Cancer Sales by Country (2017-2022)
 - 5.1.2 Americas EGFR Inhibitors for Lung Cancer Revenue by Country (2017-2022)
- 5.2 Americas EGFR Inhibitors for Lung Cancer Sales by Type
- 5.3 Americas EGFR Inhibitors for Lung Cancer Sales by Application
- 5.4 United States
- 5.5 Canada
- 5.6 Mexico
- 5.7 Brazil

6 APAC

- 6.1 APAC EGFR Inhibitors for Lung Cancer Sales by Region
 - 6.1.1 APAC EGFR Inhibitors for Lung Cancer Sales by Region (2017-2022)
 - 6.1.2 APAC EGFR Inhibitors for Lung Cancer Revenue by Region (2017-2022)
- 6.2 APAC EGFR Inhibitors for Lung Cancer Sales by Type
- 6.3 APAC EGFR Inhibitors for Lung Cancer Sales by Application
- 6.4 China
- 6.5 Japan
- 6.6 South Korea
- 6.7 Southeast Asia
- 6.8 India
- 6.9 Australia
- 6.10 China Taiwan

7 EUROPE

- 7.1 Europe EGFR Inhibitors for Lung Cancer by Country
 - 7.1.1 Europe EGFR Inhibitors for Lung Cancer Sales by Country (2017-2022)
 - 7.1.2 Europe EGFR Inhibitors for Lung Cancer Revenue by Country (2017-2022)
- 7.2 Europe EGFR Inhibitors for Lung Cancer Sales by Type
- 7.3 Europe EGFR Inhibitors for Lung Cancer Sales by Application
- 7.4 Germany

- 7.5 France
- 7.6 UK
- 7.7 Italy
- 7.8 Russia

8 MIDDLE EAST & AFRICA

- 8.1 Middle East & Africa EGFR Inhibitors for Lung Cancer by Country
 - 8.1.1 Middle East & Africa EGFR Inhibitors for Lung Cancer Sales by Country (2017-2022)
 - 8.1.2 Middle East & Africa EGFR Inhibitors for Lung Cancer Revenue by Country (2017-2022)
- 8.2 Middle East & Africa EGFR Inhibitors for Lung Cancer Sales by Type
- 8.3 Middle East & Africa EGFR Inhibitors for Lung Cancer Sales by Application
- 8.4 Egypt
- 8.5 South Africa
- 8.6 Israel
- 8.7 Turkey
- 8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

- 9.1 Market Drivers & Growth Opportunities
- 9.2 Market Challenges & Risks
- 9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

- 10.1 Raw Material and Suppliers
- 10.2 Manufacturing Cost Structure Analysis of EGFR Inhibitors for Lung Cancer
- 10.3 Manufacturing Process Analysis of EGFR Inhibitors for Lung Cancer
- 10.4 Industry Chain Structure of EGFR Inhibitors for Lung Cancer

11 MARKETING, DISTRIBUTORS AND CUSTOMER

- 11.1 Sales Channel
 - 11.1.1 Direct Channels
 - 11.1.2 Indirect Channels
- 11.2 EGFR Inhibitors for Lung Cancer Distributors

11.3 EGFR Inhibitors for Lung Cancer Customer

12 WORLD FORECAST REVIEW FOR EGFR INHIBITORS FOR LUNG CANCER BY GEOGRAPHIC REGION

12.1 Global EGFR Inhibitors for Lung Cancer Market Size Forecast by Region

12.1.1 Global EGFR Inhibitors for Lung Cancer Forecast by Region (2023-2028)

12.1.2 Global EGFR Inhibitors for Lung Cancer Annual Revenue Forecast by Region (2023-2028)

12.2 Americas Forecast by Country

12.3 APAC Forecast by Region

12.4 Europe Forecast by Country

12.5 Middle East & Africa Forecast by Country

12.6 Global EGFR Inhibitors for Lung Cancer Forecast by Type

12.7 Global EGFR Inhibitors for Lung Cancer Forecast by Application

13 KEY PLAYERS ANALYSIS

13.1 Pfizer

13.1.1 Pfizer Company Information

13.1.2 Pfizer EGFR Inhibitors for Lung Cancer Product Offered

13.1.3 Pfizer EGFR Inhibitors for Lung Cancer Sales, Revenue, Price and Gross Margin (2020-2022)

13.1.4 Pfizer Main Business Overview

13.1.5 Pfizer Latest Developments

13.2 AstraZeneca

13.2.1 AstraZeneca Company Information

13.2.2 AstraZeneca EGFR Inhibitors for Lung Cancer Product Offered

13.2.3 AstraZeneca EGFR Inhibitors for Lung Cancer Sales, Revenue, Price and Gross Margin (2020-2022)

13.2.4 AstraZeneca Main Business Overview

13.2.5 AstraZeneca Latest Developments

13.3 Genentech (Roche Group)

13.3.1 Genentech (Roche Group) Company Information

13.3.2 Genentech (Roche Group) EGFR Inhibitors for Lung Cancer Product Offered

13.3.3 Genentech (Roche Group) EGFR Inhibitors for Lung Cancer Sales, Revenue, Price and Gross Margin (2020-2022)

13.3.4 Genentech (Roche Group) Main Business Overview

13.3.5 Genentech (Roche Group) Latest Developments

13.4 Beta Pharma

13.4.1 Beta Pharma Company Information

13.4.2 Beta Pharma EGFR Inhibitors for Lung Cancer Product Offered

13.4.3 Beta Pharma EGFR Inhibitors for Lung Cancer Sales, Revenue, Price and Gross Margin (2020-2022)

13.4.4 Beta Pharma Main Business Overview

13.4.5 Beta Pharma Latest Developments

13.5 Mylan

13.5.1 Mylan Company Information

13.5.2 Mylan EGFR Inhibitors for Lung Cancer Product Offered

13.5.3 Mylan EGFR Inhibitors for Lung Cancer Sales, Revenue, Price and Gross Margin (2020-2022)

13.5.4 Mylan Main Business Overview

13.5.5 Mylan Latest Developments

13.6 Boehringer Ingelheim

13.6.1 Boehringer Ingelheim Company Information

13.6.2 Boehringer Ingelheim EGFR Inhibitors for Lung Cancer Product Offered

13.6.3 Boehringer Ingelheim EGFR Inhibitors for Lung Cancer Sales, Revenue, Price and Gross Margin (2020-2022)

13.6.4 Boehringer Ingelheim Main Business Overview

13.6.5 Boehringer Ingelheim Latest Developments

13.7 Teva Pharmaceuticals

13.7.1 Teva Pharmaceuticals Company Information

13.7.2 Teva Pharmaceuticals EGFR Inhibitors for Lung Cancer Product Offered

13.7.3 Teva Pharmaceuticals EGFR Inhibitors for Lung Cancer Sales, Revenue, Price and Gross Margin (2020-2022)

13.7.4 Teva Pharmaceuticals Main Business Overview

13.7.5 Teva Pharmaceuticals Latest Developments

13.8 Qilu Pharmaceutical

13.8.1 Qilu Pharmaceutical Company Information

13.8.2 Qilu Pharmaceutical EGFR Inhibitors for Lung Cancer Product Offered

13.8.3 Qilu Pharmaceutical EGFR Inhibitors for Lung Cancer Sales, Revenue, Price and Gross Margin (2020-2022)

13.8.4 Qilu Pharmaceutical Main Business Overview

13.8.5 Qilu Pharmaceutical Latest Developments

13.9 Betta Pharmaceuticals

13.9.1 Betta Pharmaceuticals Company Information

13.9.2 Betta Pharmaceuticals EGFR Inhibitors for Lung Cancer Product Offered

13.9.3 Betta Pharmaceuticals EGFR Inhibitors for Lung Cancer Sales, Revenue, Price

and Gross Margin (2020-2022)

13.9.4 Betta Pharmaceuticals Main Business Overview

13.9.5 Betta Pharmaceuticals Latest Developments

13.10 Haosen Pharmaceutical

13.10.1 Haosen Pharmaceutical Company Information

13.10.2 Haosen Pharmaceutical EGFR Inhibitors for Lung Cancer Product Offered

13.10.3 Haosen Pharmaceutical EGFR Inhibitors for Lung Cancer Sales, Revenue, Price and Gross Margin (2020-2022)

13.10.4 Haosen Pharmaceutical Main Business Overview

13.10.5 Haosen Pharmaceutical Latest Developments

13.11 ARIAD Pharmaceuticals

13.11.1 ARIAD Pharmaceuticals Company Information

13.11.2 ARIAD Pharmaceuticals EGFR Inhibitors for Lung Cancer Product Offered

13.11.3 ARIAD Pharmaceuticals EGFR Inhibitors for Lung Cancer Sales, Revenue, Price and Gross Margin (2020-2022)

13.11.4 ARIAD Pharmaceuticals Main Business Overview

13.11.5 ARIAD Pharmaceuticals Latest Developments

13.12 HUTCHMED

13.12.1 HUTCHMED Company Information

13.12.2 HUTCHMED EGFR Inhibitors for Lung Cancer Product Offered

13.12.3 HUTCHMED EGFR Inhibitors for Lung Cancer Sales, Revenue, Price and Gross Margin (2020-2022)

13.12.4 HUTCHMED Main Business Overview

13.12.5 HUTCHMED Latest Developments

13.13 Shanghai Ellis

13.13.1 Shanghai Ellis Company Information

13.13.2 Shanghai Ellis EGFR Inhibitors for Lung Cancer Product Offered

13.13.3 Shanghai Ellis EGFR Inhibitors for Lung Cancer Sales, Revenue, Price and Gross Margin (2020-2022)

13.13.4 Shanghai Ellis Main Business Overview

13.13.5 Shanghai Ellis Latest Developments

13.14 Genvio Pharma

13.14.1 Genvio Pharma Company Information

13.14.2 Genvio Pharma EGFR Inhibitors for Lung Cancer Product Offered

13.14.3 Genvio Pharma EGFR Inhibitors for Lung Cancer Sales, Revenue, Price and Gross Margin (2020-2022)

13.14.4 Genvio Pharma Main Business Overview

13.14.5 Genvio Pharma Latest Developments

13.15 Everest Pharmaceuticals

- 13.15.1 Everest Pharmaceuticals Company Information
- 13.15.2 Everest Pharmaceuticals EGFR Inhibitors for Lung Cancer Product Offered
- 13.15.3 Everest Pharmaceuticals EGFR Inhibitors for Lung Cancer Sales, Revenue, Price and Gross Margin (2020-2022)
- 13.15.4 Everest Pharmaceuticals Main Business Overview
- 13.15.5 Everest Pharmaceuticals Latest Developments
- 13.16 Incepta Pharmaceuticals
 - 13.16.1 Incepta Pharmaceuticals Company Information
 - 13.16.2 Incepta Pharmaceuticals EGFR Inhibitors for Lung Cancer Product Offered
 - 13.16.3 Incepta Pharmaceuticals EGFR Inhibitors for Lung Cancer Sales, Revenue, Price and Gross Margin (2020-2022)
 - 13.16.4 Incepta Pharmaceuticals Main Business Overview
 - 13.16.5 Incepta Pharmaceuticals Latest Developments
- 13.17 Jiangsu Hengrui Medicine
 - 13.17.1 Jiangsu Hengrui Medicine Company Information
 - 13.17.2 Jiangsu Hengrui Medicine EGFR Inhibitors for Lung Cancer Product Offered
 - 13.17.3 Jiangsu Hengrui Medicine EGFR Inhibitors for Lung Cancer Sales, Revenue, Price and Gross Margin (2020-2022)
 - 13.17.4 Jiangsu Hengrui Medicine Main Business Overview
 - 13.17.5 Jiangsu Hengrui Medicine Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

- Table 1. EGFR Inhibitors for Lung Cancer Annual Sales CAGR by Geographic Region (2017, 2022 & 2028) & (\$ millions)
- Table 2. EGFR Inhibitors for Lung Cancer Annual Sales CAGR by Country/Region (2017, 2022 & 2028) & (\$ millions)
- Table 3. Major Players of Gefitinib
- Table 4. Major Players of Afatinib
- Table 5. Major Players of Osimertinib
- Table 6. Major Players of Other
- Table 7. Global EGFR Inhibitors for Lung Cancer Sales by Type (2017-2022) & (K Units)
- Table 8. Global EGFR Inhibitors for Lung Cancer Sales Market Share by Type (2017-2022)
- Table 9. Global EGFR Inhibitors for Lung Cancer Revenue by Type (2017-2022) & (\$ million)
- Table 10. Global EGFR Inhibitors for Lung Cancer Revenue Market Share by Type (2017-2022)
- Table 11. Global EGFR Inhibitors for Lung Cancer Sale Price by Type (2017-2022) & (US\$/Unit)
- Table 12. Global EGFR Inhibitors for Lung Cancer Sales by Application (2017-2022) & (K Units)
- Table 13. Global EGFR Inhibitors for Lung Cancer Sales Market Share by Application (2017-2022)
- Table 14. Global EGFR Inhibitors for Lung Cancer Revenue by Application (2017-2022)
- Table 15. Global EGFR Inhibitors for Lung Cancer Revenue Market Share by Application (2017-2022)
- Table 16. Global EGFR Inhibitors for Lung Cancer Sale Price by Application (2017-2022) & (US\$/Unit)
- Table 17. Global EGFR Inhibitors for Lung Cancer Sales by Company (2020-2022) & (K Units)
- Table 18. Global EGFR Inhibitors for Lung Cancer Sales Market Share by Company (2020-2022)
- Table 19. Global EGFR Inhibitors for Lung Cancer Revenue by Company (2020-2022) (\$ Millions)
- Table 20. Global EGFR Inhibitors for Lung Cancer Revenue Market Share by Company (2020-2022)

Table 21. Global EGFR Inhibitors for Lung Cancer Sale Price by Company (2020-2022) & (US\$/Unit)

Table 22. Key Manufacturers EGFR Inhibitors for Lung Cancer Producing Area Distribution and Sales Area

Table 23. Players EGFR Inhibitors for Lung Cancer Products Offered

Table 24. EGFR Inhibitors for Lung Cancer Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)

Table 25. New Products and Potential Entrants

Table 26. Mergers & Acquisitions, Expansion

Table 27. Global EGFR Inhibitors for Lung Cancer Sales by Geographic Region (2017-2022) & (K Units)

Table 28. Global EGFR Inhibitors for Lung Cancer Sales Market Share Geographic Region (2017-2022)

Table 29. Global EGFR Inhibitors for Lung Cancer Revenue by Geographic Region (2017-2022) & (\$ millions)

Table 30. Global EGFR Inhibitors for Lung Cancer Revenue Market Share by Geographic Region (2017-2022)

Table 31. Global EGFR Inhibitors for Lung Cancer Sales by Country/Region (2017-2022) & (K Units)

Table 32. Global EGFR Inhibitors for Lung Cancer Sales Market Share by Country/Region (2017-2022)

Table 33. Global EGFR Inhibitors for Lung Cancer Revenue by Country/Region (2017-2022) & (\$ millions)

Table 34. Global EGFR Inhibitors for Lung Cancer Revenue Market Share by Country/Region (2017-2022)

Table 35. Americas EGFR Inhibitors for Lung Cancer Sales by Country (2017-2022) & (K Units)

Table 36. Americas EGFR Inhibitors for Lung Cancer Sales Market Share by Country (2017-2022)

Table 37. Americas EGFR Inhibitors for Lung Cancer Revenue by Country (2017-2022) & (\$ Millions)

Table 38. Americas EGFR Inhibitors for Lung Cancer Revenue Market Share by Country (2017-2022)

Table 39. Americas EGFR Inhibitors for Lung Cancer Sales by Type (2017-2022) & (K Units)

Table 40. Americas EGFR Inhibitors for Lung Cancer Sales Market Share by Type (2017-2022)

Table 41. Americas EGFR Inhibitors for Lung Cancer Sales by Application (2017-2022) & (K Units)

- Table 42. Americas EGFR Inhibitors for Lung Cancer Sales Market Share by Application (2017-2022)
- Table 43. APAC EGFR Inhibitors for Lung Cancer Sales by Region (2017-2022) & (K Units)
- Table 44. APAC EGFR Inhibitors for Lung Cancer Sales Market Share by Region (2017-2022)
- Table 45. APAC EGFR Inhibitors for Lung Cancer Revenue by Region (2017-2022) & (\$ Millions)
- Table 46. APAC EGFR Inhibitors for Lung Cancer Revenue Market Share by Region (2017-2022)
- Table 47. APAC EGFR Inhibitors for Lung Cancer Sales by Type (2017-2022) & (K Units)
- Table 48. APAC EGFR Inhibitors for Lung Cancer Sales Market Share by Type (2017-2022)
- Table 49. APAC EGFR Inhibitors for Lung Cancer Sales by Application (2017-2022) & (K Units)
- Table 50. APAC EGFR Inhibitors for Lung Cancer Sales Market Share by Application (2017-2022)
- Table 51. Europe EGFR Inhibitors for Lung Cancer Sales by Country (2017-2022) & (K Units)
- Table 52. Europe EGFR Inhibitors for Lung Cancer Sales Market Share by Country (2017-2022)
- Table 53. Europe EGFR Inhibitors for Lung Cancer Revenue by Country (2017-2022) & (\$ Millions)
- Table 54. Europe EGFR Inhibitors for Lung Cancer Revenue Market Share by Country (2017-2022)
- Table 55. Europe EGFR Inhibitors for Lung Cancer Sales by Type (2017-2022) & (K Units)
- Table 56. Europe EGFR Inhibitors for Lung Cancer Sales Market Share by Type (2017-2022)
- Table 57. Europe EGFR Inhibitors for Lung Cancer Sales by Application (2017-2022) & (K Units)
- Table 58. Europe EGFR Inhibitors for Lung Cancer Sales Market Share by Application (2017-2022)
- Table 59. Middle East & Africa EGFR Inhibitors for Lung Cancer Sales by Country (2017-2022) & (K Units)
- Table 60. Middle East & Africa EGFR Inhibitors for Lung Cancer Sales Market Share by Country (2017-2022)
- Table 61. Middle East & Africa EGFR Inhibitors for Lung Cancer Revenue by Country

(2017-2022) & (\$ Millions)

Table 62. Middle East & Africa EGFR Inhibitors for Lung Cancer Revenue Market Share by Country (2017-2022)

Table 63. Middle East & Africa EGFR Inhibitors for Lung Cancer Sales by Type (2017-2022) & (K Units)

Table 64. Middle East & Africa EGFR Inhibitors for Lung Cancer Sales Market Share by Type (2017-2022)

Table 65. Middle East & Africa EGFR Inhibitors for Lung Cancer Sales by Application (2017-2022) & (K Units)

Table 66. Middle East & Africa EGFR Inhibitors for Lung Cancer Sales Market Share by Application (2017-2022)

Table 67. Key Market Drivers & Growth Opportunities of EGFR Inhibitors for Lung Cancer

Table 68. Key Market Challenges & Risks of EGFR Inhibitors for Lung Cancer

Table 69. Key Industry Trends of EGFR Inhibitors for Lung Cancer

Table 70. EGFR Inhibitors for Lung Cancer Raw Material

Table 71. Key Suppliers of Raw Materials

Table 72. EGFR Inhibitors for Lung Cancer Distributors List

Table 73. EGFR Inhibitors for Lung Cancer Customer List

Table 74. Global EGFR Inhibitors for Lung Cancer Sales Forecast by Region (2023-2028) & (K Units)

Table 75. Global EGFR Inhibitors for Lung Cancer Sales Market Forecast by Region

Table 76. Global EGFR Inhibitors for Lung Cancer Revenue Forecast by Region (2023-2028) & (\$ millions)

Table 77. Global EGFR Inhibitors for Lung Cancer Revenue Market Share Forecast by Region (2023-2028)

Table 78. Americas EGFR Inhibitors for Lung Cancer Sales Forecast by Country (2023-2028) & (K Units)

Table 79. Americas EGFR Inhibitors for Lung Cancer Revenue Forecast by Country (2023-2028) & (\$ millions)

Table 80. APAC EGFR Inhibitors for Lung Cancer Sales Forecast by Region (2023-2028) & (K Units)

Table 81. APAC EGFR Inhibitors for Lung Cancer Revenue Forecast by Region (2023-2028) & (\$ millions)

Table 82. Europe EGFR Inhibitors for Lung Cancer Sales Forecast by Country (2023-2028) & (K Units)

Table 83. Europe EGFR Inhibitors for Lung Cancer Revenue Forecast by Country (2023-2028) & (\$ millions)

Table 84. Middle East & Africa EGFR Inhibitors for Lung Cancer Sales Forecast by

Country (2023-2028) & (K Units)

Table 85. Middle East & Africa EGFR Inhibitors for Lung Cancer Revenue Forecast by Country (2023-2028) & (\$ millions)

Table 86. Global EGFR Inhibitors for Lung Cancer Sales Forecast by Type (2023-2028) & (K Units)

Table 87. Global EGFR Inhibitors for Lung Cancer Sales Market Share Forecast by Type (2023-2028)

Table 88. Global EGFR Inhibitors for Lung Cancer Revenue Forecast by Type (2023-2028) & (\$ Millions)

Table 89. Global EGFR Inhibitors for Lung Cancer Revenue Market Share Forecast by Type (2023-2028)

Table 90. Global EGFR Inhibitors for Lung Cancer Sales Forecast by Application (2023-2028) & (K Units)

Table 91. Global EGFR Inhibitors for Lung Cancer Sales Market Share Forecast by Application (2023-2028)

Table 92. Global EGFR Inhibitors for Lung Cancer Revenue Forecast by Application (2023-2028) & (\$ Millions)

Table 93. Global EGFR Inhibitors for Lung Cancer Revenue Market Share Forecast by Application (2023-2028)

Table 94. Pfizer Basic Information, EGFR Inhibitors for Lung Cancer Manufacturing Base, Sales Area and Its Competitors

Table 95. Pfizer EGFR Inhibitors for Lung Cancer Product Offered

Table 96. Pfizer EGFR Inhibitors for Lung Cancer Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)

Table 97. Pfizer Main Business

Table 98. Pfizer Latest Developments

Table 99. AstraZeneca Basic Information, EGFR Inhibitors for Lung Cancer Manufacturing Base, Sales Area and Its Competitors

Table 100. AstraZeneca EGFR Inhibitors for Lung Cancer Product Offered

Table 101. AstraZeneca EGFR Inhibitors for Lung Cancer Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)

Table 102. AstraZeneca Main Business

Table 103. AstraZeneca Latest Developments

Table 104. Genentech (Roche Group) Basic Information, EGFR Inhibitors for Lung Cancer Manufacturing Base, Sales Area and Its Competitors

Table 105. Genentech (Roche Group) EGFR Inhibitors for Lung Cancer Product Offered

Table 106. Genentech (Roche Group) EGFR Inhibitors for Lung Cancer Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)

Table 107. Genentech (Roche Group) Main Business

- Table 108. Genentech (Roche Group) Latest Developments
- Table 109. Beta Pharma Basic Information, EGFR Inhibitors for Lung Cancer Manufacturing Base, Sales Area and Its Competitors
- Table 110. Beta Pharma EGFR Inhibitors for Lung Cancer Product Offered
- Table 111. Beta Pharma EGFR Inhibitors for Lung Cancer Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)
- Table 112. Beta Pharma Main Business
- Table 113. Beta Pharma Latest Developments
- Table 114. Mylan Basic Information, EGFR Inhibitors for Lung Cancer Manufacturing Base, Sales Area and Its Competitors
- Table 115. Mylan EGFR Inhibitors for Lung Cancer Product Offered
- Table 116. Mylan EGFR Inhibitors for Lung Cancer Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)
- Table 117. Mylan Main Business
- Table 118. Mylan Latest Developments
- Table 119. Boehringer Ingelheim Basic Information, EGFR Inhibitors for Lung Cancer Manufacturing Base, Sales Area and Its Competitors
- Table 120. Boehringer Ingelheim EGFR Inhibitors for Lung Cancer Product Offered
- Table 121. Boehringer Ingelheim EGFR Inhibitors for Lung Cancer Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)
- Table 122. Boehringer Ingelheim Main Business
- Table 123. Boehringer Ingelheim Latest Developments
- Table 124. Teva Pharmaceuticals Basic Information, EGFR Inhibitors for Lung Cancer Manufacturing Base, Sales Area and Its Competitors
- Table 125. Teva Pharmaceuticals EGFR Inhibitors for Lung Cancer Product Offered
- Table 126. Teva Pharmaceuticals EGFR Inhibitors for Lung Cancer Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)
- Table 127. Teva Pharmaceuticals Main Business
- Table 128. Teva Pharmaceuticals Latest Developments
- Table 129. Qilu Pharmaceutical Basic Information, EGFR Inhibitors for Lung Cancer Manufacturing Base, Sales Area and Its Competitors
- Table 130. Qilu Pharmaceutical EGFR Inhibitors for Lung Cancer Product Offered
- Table 131. Qilu Pharmaceutical EGFR Inhibitors for Lung Cancer Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)
- Table 132. Qilu Pharmaceutical Main Business
- Table 133. Qilu Pharmaceutical Latest Developments
- Table 134. Betta Pharmaceuticals Basic Information, EGFR Inhibitors for Lung Cancer Manufacturing Base, Sales Area and Its Competitors
- Table 135. Betta Pharmaceuticals EGFR Inhibitors for Lung Cancer Product Offered

Table 136. Betta Pharmaceuticals EGFR Inhibitors for Lung Cancer Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)

Table 137. Betta Pharmaceuticals Main Business

Table 138. Betta Pharmaceuticals Latest Developments

Table 139. Haosen Pharmaceutical Basic Information, EGFR Inhibitors for Lung Cancer Manufacturing Base, Sales Area and Its Competitors

Table 140. Haosen Pharmaceutical EGFR Inhibitors for Lung Cancer Product Offered

Table 141. Haosen Pharmaceutical EGFR Inhibitors for Lung Cancer Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)

Table 142. Haosen Pharmaceutical Main Business

Table 143. Haosen Pharmaceutical Latest Developments

Table 144. ARIAD Pharmaceuticals Basic Information, EGFR Inhibitors for Lung Cancer Manufacturing Base, Sales Area and Its Competitors

Table 145. ARIAD Pharmaceuticals EGFR Inhibitors for Lung Cancer Product Offered

Table 146. ARIAD Pharmaceuticals EGFR Inhibitors for Lung Cancer Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)

Table 147. ARIAD Pharmaceuticals Main Business

Table 148. ARIAD Pharmaceuticals Latest Developments

Table 149. HUTCHMED Basic Information, EGFR Inhibitors for Lung Cancer Manufacturing Base, Sales Area and Its Competitors

Table 150. HUTCHMED EGFR Inhibitors for Lung Cancer Product Offered

Table 151. HUTCHMED EGFR Inhibitors for Lung Cancer Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)

Table 152. HUTCHMED Main Business

Table 153. HUTCHMED Latest Developments

Table 154. Shanghai Ellis Basic Information, EGFR Inhibitors for Lung Cancer Manufacturing Base, Sales Area and Its Competitors

Table 155. Shanghai Ellis EGFR Inhibitors for Lung Cancer Product Offered

Table 156. Shanghai Ellis EGFR Inhibitors for Lung Cancer Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)

Table 157. Shanghai Ellis Main Business

Table 158. Shanghai Ellis Latest Developments

Table 159. Genvio Pharma Basic Information, EGFR Inhibitors for Lung Cancer Manufacturing Base, Sales Area and Its Competitors

Table 160. Genvio Pharma EGFR Inhibitors for Lung Cancer Product Offered

Table 161. Genvio Pharma EGFR Inhibitors for Lung Cancer Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)

Table 162. Genvio Pharma Main Business

Table 163. Genvio Pharma Latest Developments

Table 164. Everest Pharmaceuticals Basic Information, EGFR Inhibitors for Lung Cancer Manufacturing Base, Sales Area and Its Competitors

Table 165. Everest Pharmaceuticals EGFR Inhibitors for Lung Cancer Product Offered

Table 166. Everest Pharmaceuticals EGFR Inhibitors for Lung Cancer Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)

Table 167. Everest Pharmaceuticals Main Business

Table 168. Everest Pharmaceuticals Latest Developments

Table 169. Incepta Pharmaceuticals Basic Information, EGFR Inhibitors for Lung Cancer Manufacturing Base, Sales Area and Its Competitors

Table 170. Incepta Pharmaceuticals EGFR Inhibitors for Lung Cancer Product Offered

Table 171. Incepta Pharmaceuticals EGFR Inhibitors for Lung Cancer Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)

Table 172. Incepta Pharmaceuticals Main Business

Table 173. Incepta Pharmaceuticals Latest Developments

Table 174. Jiangsu Hengrui Medicine Basic Information, EGFR Inhibitors for Lung Cancer Manufacturing Base, Sales Area and Its Competitors

Table 175. Jiangsu Hengrui Medicine EGFR Inhibitors for Lung Cancer Product Offered

Table 176. Jiangsu Hengrui Medicine EGFR Inhibitors for Lung Cancer Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)

Table 177. Jiangsu Hengrui Medicine Main Business

Table 178. Jiangsu Hengrui Medicine Latest Developments

List Of Figures

LIST OF FIGURES

- Figure 1. Picture of EGFR Inhibitors for Lung Cancer
- Figure 2. EGFR Inhibitors for Lung Cancer Report Years Considered
- Figure 3. Research Objectives
- Figure 4. Research Methodology
- Figure 5. Research Process and Data Source
- Figure 6. Global EGFR Inhibitors for Lung Cancer Sales Growth Rate 2017-2028 (K Units)
- Figure 7. Global EGFR Inhibitors for Lung Cancer Revenue Growth Rate 2017-2028 (\$ Millions)
- Figure 8. EGFR Inhibitors for Lung Cancer Sales by Region (2021 & 2028) & (\$ millions)
- Figure 9. Product Picture of Gefitinib
- Figure 10. Product Picture of Afatinib
- Figure 11. Product Picture of Osimertinib
- Figure 12. Product Picture of Other
- Figure 13. Global EGFR Inhibitors for Lung Cancer Sales Market Share by Type in 2021
- Figure 14. Global EGFR Inhibitors for Lung Cancer Revenue Market Share by Type (2017-2022)
- Figure 15. EGFR Inhibitors for Lung Cancer Consumed in Medical Care
- Figure 16. Global EGFR Inhibitors for Lung Cancer Market: Medical Care (2017-2022) & (K Units)
- Figure 17. EGFR Inhibitors for Lung Cancer Consumed in Experiment
- Figure 18. Global EGFR Inhibitors for Lung Cancer Market: Experiment (2017-2022) & (K Units)
- Figure 19. EGFR Inhibitors for Lung Cancer Consumed in Others
- Figure 20. Global EGFR Inhibitors for Lung Cancer Market: Others (2017-2022) & (K Units)
- Figure 21. Global EGFR Inhibitors for Lung Cancer Sales Market Share by Application (2017-2022)
- Figure 22. Global EGFR Inhibitors for Lung Cancer Revenue Market Share by Application in 2021
- Figure 23. EGFR Inhibitors for Lung Cancer Revenue Market by Company in 2021 (\$ Million)
- Figure 24. Global EGFR Inhibitors for Lung Cancer Revenue Market Share by Company in 2021

Figure 25. Global EGFR Inhibitors for Lung Cancer Sales Market Share by Geographic Region (2017-2022)

Figure 26. Global EGFR Inhibitors for Lung Cancer Revenue Market Share by Geographic Region in 2021

Figure 27. Global EGFR Inhibitors for Lung Cancer Sales Market Share by Region (2017-2022)

Figure 28. Global EGFR Inhibitors for Lung Cancer Revenue Market Share by Country/Region in 2021

Figure 29. Americas EGFR Inhibitors for Lung Cancer Sales 2017-2022 (K Units)

Figure 30. Americas EGFR Inhibitors for Lung Cancer Revenue 2017-2022 (\$ Millions)

Figure 31. APAC EGFR Inhibitors for Lung Cancer Sales 2017-2022 (K Units)

Figure 32. APAC EGFR Inhibitors for Lung Cancer Revenue 2017-2022 (\$ Millions)

Figure 33. Europe EGFR Inhibitors for Lung Cancer Sales 2017-2022 (K Units)

Figure 34. Europe EGFR Inhibitors for Lung Cancer Revenue 2017-2022 (\$ Millions)

Figure 35. Middle East & Africa EGFR Inhibitors for Lung Cancer Sales 2017-2022 (K Units)

Figure 36. Middle East & Africa EGFR Inhibitors for Lung Cancer Revenue 2017-2022 (\$ Millions)

Figure 37. Americas EGFR Inhibitors for Lung Cancer Sales Market Share by Country in 2021

Figure 38. Americas EGFR Inhibitors for Lung Cancer Revenue Market Share by Country in 2021

Figure 39. United States EGFR Inhibitors for Lung Cancer Revenue Growth 2017-2022 (\$ Millions)

Figure 40. Canada EGFR Inhibitors for Lung Cancer Revenue Growth 2017-2022 (\$ Millions)

Figure 41. Mexico EGFR Inhibitors for Lung Cancer Revenue Growth 2017-2022 (\$ Millions)

Figure 42. Brazil EGFR Inhibitors for Lung Cancer Revenue Growth 2017-2022 (\$ Millions)

Figure 43. APAC EGFR Inhibitors for Lung Cancer Sales Market Share by Region in 2021

Figure 44. APAC EGFR Inhibitors for Lung Cancer Revenue Market Share by Regions in 2021

Figure 45. China EGFR Inhibitors for Lung Cancer Revenue Growth 2017-2022 (\$ Millions)

Figure 46. Japan EGFR Inhibitors for Lung Cancer Revenue Growth 2017-2022 (\$ Millions)

Figure 47. South Korea EGFR Inhibitors for Lung Cancer Revenue Growth 2017-2022

(\$ Millions)

Figure 48. Southeast Asia EGFR Inhibitors for Lung Cancer Revenue Growth

2017-2022 (\$ Millions)

Figure 49. India EGFR Inhibitors for Lung Cancer Revenue Growth 2017-2022 (\$

Millions)

Figure 50. Australia EGFR Inhibitors for Lung Cancer Revenue Growth 2017-2022 (\$

Millions)

Figure 51. Europe EGFR Inhibitors for Lung Cancer Sales Market Share by Country in 2021

Figure 52. Europe EGFR Inhibitors for Lung Cancer Revenue Market Share by Country in 2021

Figure 53. Germany EGFR Inhibitors for Lung Cancer Revenue Growth 2017-2022 (\$ Millions)

Figure 54. France EGFR Inhibitors for Lung Cancer Revenue Growth 2017-2022 (\$ Millions)

Figure 55. UK EGFR Inhibitors for Lung Cancer Revenue Growth 2017-2022 (\$ Millions)

Figure 56. Italy EGFR Inhibitors for Lung Cancer Revenue Growth 2017-2022 (\$ Millions)

Figure 57. Russia EGFR Inhibitors for Lung Cancer Revenue Growth 2017-2022 (\$ Millions)

Figure 58. Middle East & Africa EGFR Inhibitors for Lung Cancer Sales Market Share by Country in 2021

Figure 59. Middle East & Africa EGFR Inhibitors for Lung Cancer Revenue Market Share by Country in 2021

Figure 60. Egypt EGFR Inhibitors for Lung Cancer Revenue Growth 2017-2022 (\$ Millions)

Figure 61. South Africa EGFR Inhibitors for Lung Cancer Revenue Growth 2017-2022 (\$ Millions)

Figure 62. Israel EGFR Inhibitors for Lung Cancer Revenue Growth 2017-2022 (\$ Millions)

Figure 63. Turkey EGFR Inhibitors for Lung Cancer Revenue Growth 2017-2022 (\$ Millions)

Figure 64. GCC Country EGFR Inhibitors for Lung Cancer Revenue Growth 2017-2022 (\$ Millions)

Figure 65. Manufacturing Cost Structure Analysis of EGFR Inhibitors for Lung Cancer in 2021

Figure 66. Manufacturing Process Analysis of EGFR Inhibitors for Lung Cancer

Figure 67. Industry Chain Structure of EGFR Inhibitors for Lung Cancer

Figure 68. Channels of Distribution

Figure 69. Distributors Profiles

I would like to order

Product name: Global EGFR Inhibitors for Lung Cancer Market Growth 2022-2028

Product link: <https://marketpublishers.com/r/GAC6B0D9A0EBEN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GAC6B0D9A0EBEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970